ライフサイエンスコーパス: rifapentine

1 ng a 12-dose regimen of weekly isoniazid and rifapentine.

2 hieve highly active once-weekly therapy with rifapentine.

3 wed increased susceptibility to rifampin and rifapentine.

4 evaluation of the safety and tolerability of rifapentine 1,200 mg is warranted.

5 Only one discontinuation, in the rifapentine 1,200-mg arm, was due to an adverse event po

6 ve pulmonary tuberculosis were randomized to rifapentine 10 mg/kg/dose or rifampin 10 mg/kg/dose, adm

7 .4% (P = 0.29), and 94.7% (P = 0.049) in the rifapentine 10, 15, and 20 mg/kg groups.

8 ositive pulmonary tuberculosis were assigned rifapentine 10, 15, or 20 mg/kg or rifampin 10 mg/kg dai

9 were similar across groups (rifampin, 8.2%; rifapentine 10, 15, or 20 mg/kg, 3.4, 2.5, and 7.4%, res

10 continuation phase regimen of isoniazid plus rifapentine (10 mg/kg) is inferior to standard twice-wee

11 detected between once-weekly isoniazid plus rifapentine (15 mg/kg) and the Denver regimen.

12 ng activity of once-weekly moxifloxacin plus rifapentine (15 mg/kg) was significantly greater than th

13 I with 3 months of once-weekly isoniazid and rifapentine (3HP) administered under directly observed t

14 kly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious as 9 months of ison

15 pin (3RH) and three months of isoniazid plus rifapentine (3RPTH).

16 Once-weekly rifapentine 600 mg plus isoniazid (INH) during the conti

17 (6%), 2 of 51 (4%), and 3 of 47 (6%) in the rifapentine 600-, 900-, and 1,200-mg treatment arms, res

18 Rifapentine 900-mg, once-weekly dosing appears to be saf

19 f directly observed once-weekly therapy with rifapentine (900 mg) plus isoniazid (900 mg) (combinatio

20 not taking antiretroviral therapy to receive rifapentine (900 mg) plus isoniazid (900 mg) weekly for

21 Rifapentine administered 5 days per week has potent acti

22 onths followed by moxifloxacin and 900 mg of rifapentine administered twice weekly for 2 months; or a

23 Three months of a once-weekly combination of rifapentine and isoniazid for treatment of latent tuberc

24 died the interaction of efavirenz with daily rifapentine and isoniazid in human immunodeficiency viru

25 Treatment with the combination of rifapentine and isoniazid was as effective as isoniazid-

26 mean ratio (GMR) of values before and during rifapentine and isoniazid was calculated.

27 Participants receiving daily rifapentine and isoniazid with efavirenz had pharmacokin

28 included weekly administration of high-dose rifapentine and moxifloxacin was as effective as the con

29 e evaluated new treatment regimens including rifapentine and moxifloxacin, and assessed the potential

30 and protein-bound) plasma concentrations of rifapentine and of desacetyl rifapentine detected for mo

31 ression analyses, AUC(0-infinity) values for rifapentine and the active 25-desacetyl metabolite were

32 t the binding sites for rifampin, rifabutin, rifapentine, and sorangicin A are shared, whereas the bi

33 ing two rifamycin derivatives, rifabutin and rifapentine, and streptolydigin and sorangicin A, which

34 er among rifapentine recipients who had high rifapentine areas under the concentration-time curve.

35 The pharmacokinetics of rifapentine at 600, 900, and 1,200 mg were studied durin

36 ility, safety, and antimicrobial activity of rifapentine at daily doses of up to 20 mg/kg of body wei

37 ospective, randomized, double-blind trial of rifapentine at three doses (600, 900, and 1,200 mg) plus

38 nfinity)) increased significantly with dose (rifapentine AUC(0- infinity): 296, 410, and 477 microg.h

39 of 35 cases; 3%) and not linked with higher rifapentine AUC(0-infinity) or peak concentration.

40 sterilizing activity of improved once-weekly rifapentine-based continuation phase regimens in a murin

41 ticipants received once-weekly isoniazid and rifapentine by direct observation, self-administration w

42 tion and safety of once-weekly isoniazid and rifapentine by self-administration versus direct observa

43 Three-month, once-weekly regimens of rifapentine combined with either isoniazid or moxifloxac

44 e efficacy of the once-weekly isoniazid plus rifapentine continuation phase regimen can be increased

45 atients treated with a once-weekly isoniazid/rifapentine continuation-phase regimen.

46 for isoniazid and an increase in the dose of rifapentine could augment the activity of once-weekly re

47 ncentrations of rifapentine and of desacetyl rifapentine detected for more than 36 hours after cleara

48 orts further trials to determine the optimal rifapentine dose for treatment of tuberculosis.

49 The safety and tolerability of higher rifapentine doses need to be determined.

50 h/ml of rifapentine drug exposure (as measured by AUC) was 0.11

51 nonlinear mixed effects model in relation to rifapentine exposure (area under the concentration-time

52 Increasing rifapentine exposure is associated with a higher rate of

53 Moreover, rifapentine exposure, but not assigned dose, was signifi

54 d to determine if regimens that deliver high rifapentine exposures can shorten treatment duration to

55 High rifapentine exposures were associated with high levels o

56 Once-weekly isoniazid and rifapentine for 12 doses is effective but limited by req

57 kly dose of both moxifloxacin and 1200 mg of rifapentine for 4 months.

58 safety, and antimicrobial activity of daily rifapentine for pulmonary tuberculosis treatment.

59 Assessment of higher exposures to rifapentine for tuberculosis treatment is warranted.

60 rifampin group and 133 of 196 (67.9%) in the rifapentine group (difference, 2.8%; 95% CI: -6.9, 12.4)

61 p and 171 of 198 participants (86.4%) in the rifapentine group (difference, 3.0%; 95% confidence inte

62 f five relapses in the once-weekly isoniazid/rifapentine group had monoresistance to rifamycin, compa

63 up and 40 of 275 participants (14.5%) in the rifapentine group prematurely discontinued treatment (P=

64 of 30 patients in the once-weekly isoniazid/rifapentine group relapsed, compared with three of 31 pa

65 Rifapentine has potent activity in mouse models of tuber

66 hort-course directly observed isoniazid plus rifapentine (INH/RPT) combination could have potential a

67 Rifapentine is a cyclopentyl-substituted rifamycin whose

68 r death were 3.1 per 100 person-years in the rifapentine-isoniazid group, 2.9 per 100 person-years in

69 Evidence existed for efficacy of weekly rifapentine-isoniazid regimens compared with no treatmen

70 niazid (INH), 4-month rifampin (RIF), weekly rifapentine/isoniazid (RPT/INH) for 12 weeks, or no trea

71 d 9.8 L/hour (IQR, 7.04-15.59 L/hour) during rifapentine/isoniazid treatment (GMR, 1.04 [90% confiden

72 or 3 months of directly observed once-weekly rifapentine (maximum dose, 900 mg) plus isoniazid (maxim

73 h failure/relapse with once-weekly isoniazid/rifapentine (median isoniazid area under the concentrati

74 Together, these findings suggest that rifapentine, moxifloxacin, and, perhaps, therapeutic DNA

75 andomly assigned 900 mg isoniazid and 600 mg rifapentine once weekly, or 900 mg isoniazid and 600 mg

76 Neither a 3-month course of intermittent rifapentine or rifampin with isoniazid nor continuous is

77 ated with outcome with once-weekly isoniazid/rifapentine (p = 0.03) but not twice-weekly isoniazid/ri

78 Four weeks of daily rifapentine plus isoniazid can be coadministered with ef

79 Weekly rifapentine plus isoniazid for 3 months (3HP) is as effe

80 The use of rifapentine plus isoniazid for 3 months was as effective

81 n = 6886) found that 3 months of once-weekly rifapentine plus isoniazid was noninferior to 9 months o

82 the end of intensive phase was higher among rifapentine recipients who had high rifapentine areas un

83 The rifapentine regimen was safe but not significantly more

84 not be treated with a once-weekly isoniazid/rifapentine regimen.

85 Twelve-week rifapentine (RPT)/isoniazid (INH) is effective for LTBI

86 hange of CT was higher in subjects receiving rifapentine than in subjects receiving standard-dose rif

87 To understand why once-weekly isoniazid/rifapentine therapy for tuberculosis was less effective

88 for isoniazid and by increasing the dose of rifapentine to a clinically acceptable level of 15 mg/kg

89 self-administered, once-weekly isoniazid and rifapentine to treat latent tuberculosis infection in th

90 red the antimicrobial activity and safety of rifapentine vs rifampin during the first 8 weeks of pulm

91 d for 3-mo regimens containing rifampicin or rifapentine was 19-100%.

92 Rifapentine was more potent than rifampin prior to devel

93 Daily rifapentine was well-tolerated and safe.

94 pared a once-weekly regimen of isoniazid and rifapentine with twice weekly isoniazid and rifampin in